Details for New Drug Application (NDA): 209209
✉ Email this page to a colleague
NDA 209209 describes MEFENAMIC ACID, which is a drug marketed by Belcher, Chartwell Rx, Lupin Ltd, Micro Labs, and Nostrum Labs Inc, and is included in five NDAs. It is available from six suppliers. Additional details are available on the MEFENAMIC ACID profile page.
The generic ingredient in MEFENAMIC ACID is mefenamic acid. There are thirteen drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the mefenamic acid profile page.
The generic ingredient in MEFENAMIC ACID is mefenamic acid. There are thirteen drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the mefenamic acid profile page.
Summary for 209209
| Tradename: | MEFENAMIC ACID |
| Applicant: | Chartwell Rx |
| Ingredient: | mefenamic acid |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 209209
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | 250MG | ||||
| Approval Date: | Sep 18, 2020 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
